Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.
Commentary|Podcasts|September 18, 2026
Episode 175: Advancing the Ways of Treating Cluster Headache
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
Advertisement
Episode 171 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
In episode 175, “Advancing the Ways of Treating Cluster Headache,” Jennifer Fokas, MD, and Minali Nigam, MD, neurologists at
The conversation also covered practical approaches to acute and preventive treatment, including high-flow oxygen via non-rebreather mask, subcutaneous sumatriptan, bridge therapies, and preventive options such as high-dose verapamil and, in selected cases, lithium. The physicians also review emerging and adjunctive options while noting limitations in evidence, indications, and access. They concluded by underscoring the need for clinician preparedness and tailored therapy to enable more assertive and appropriate management of cluster headache.
The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Approves Zilganersen, First Treatment for Alexander Disease FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug FDA Approves Apitegromab for Spinal Muscular Atrophy
EPISODE BREAKDOWN
- 1:54 – Biggest unmet need in cluster headache
- 5:01 – Importance of multimodal acute management and access issues
- 7:39 – Neurology News Minute
- 10:03 – Emerging and experimental therapies
- 13:03– Preventive options and special situations
- 17:51 – Key clinical takeaway: preparation and access to therapies
Hoping to listen on your favorite podcast app? See below:
REFERENCE
1. Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI. Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(1):117-124. doi:10.1111/head.14021
Advertisement
Related to this article
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.
A review of 12 studies showed that maternal migraine was linked to a higher likelihood of infant colic, and that infant colic was in turn linked to a higher risk of migraine later in childhood.
FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.
The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.
The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.
The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
2
Exploring the Unmet Needs in CIDP
3
RIPK1 Inhibitor Fails to Slow Functional Decline in Phase 2 ALS Trial
4
Previewing Advancements in Hypersomnia Diagnosis and Treatment
5